RecruitMe Clinical Trial
A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating NEOadjuvant immunotherapy Based Combinations in Patients with Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC)
A study of Neoadjuvant Immunotherapy Combinations in Patients with Pancreatic Ductal Adenocarcinoma (NEOiPANC)
| Sponsor: | Genentech |
| Enrolling: | Male and Female Patients |
| Minimum Age: | 18 years old |
| IRB Number: | AAAS1908 |
| U.S. Government ID: | NCT03979066 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to determine if treatment with atezolizumab and PEGylated Recombinant Human Hyaluronidase (PEGPH20), given before and after surgery, in addition to chemotherapy, is safe and if it can further increase the chance of cure. Approximately 40 patients will be asked to participate in this study, 20 randomized (chance of flipping a coin) to receive atezolizumab, and 20 randomized (chance of flipping a coin) to receive the combination of atezolizumab plus PEGPH20.
